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ABSTRACT
The reaction of chloroheterocycles with some isoxazolones under microwave irradiation and under solvent-free conditions to
give the corresponding mono isoxazolinyl derivatives is reported. The main advantages of this method are: (i) elimination of the
nitrogen gas (N2), (ii) solvent-free conditions, (iii) microwave irradiation, (iv) avoiding the use of silica gel for purification of the
products, and (v) higher and shorter reaction times. These compounds have potential applications as DNA intercalators.
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1. Introduction
Isoxazolones derivatives are important heterocyclic compounds
with a wide range of reported biological activities. Recently,
several N-substituted isoxazol-5(2H)-ones such as the
N-(cyanoethyl) derivative have been isolated from root exudates
of sweet pea seedlings, and they were shown to effect protec-
tion against infection.1 In addition, isoxazol-5(2H)-ones exhibit
herbicidal,2 bacterical3 and anticholestermic and hypolipemic
properties.4
Khalafy and co-workers have reported5,6 the synthesis of new
N-substituted derivatives of 3-arylaminoisoxazol-5(2H)-ones
1a–c with benzoxazole and benzothiazole at nitrogen in chloro-
form under reflux conditions to produce the corresponding
N-benzoxazole and N-benzothiazole derivatives 2a–c and 3a–c
(Scheme 1).
We have also reported7–10 the reaction of 2-chloro-5-nitro-
pyridine and 2,3-dichloroquinoxaline with isoxazolone11 1 in the
absence of solvent by heating the required regents in a sealed
tube at 130 °C for an hour to give N-substituted derivatives 4
and 5 (Scheme 2). Here we describe the synthesis of N-aryl iso-
xazolones in solid phase under microwave irradiation in higher
yields and shorter reaction times.
2. Results and Discussion
The isoxazolones 1a–c were prepared from the reaction of the
corresponding thiocarbamates 6a–c with hydroxylamine by the
general method of Worrall11 (Scheme 3).
The synthesis of the starting material generally involves the
displacement of an activated halide in a heterocyclic system by a
suitable 2H-isoxazolone. Thus, reaction of isoxazolones 1a–c
with 2-chlorobenzoxazole, 2-chlorobenzothiazole, 2-chloro-5-
nitropyridine and 2-chloropyrimidine in solid phase under
microwave irradiation afforded the corresponding N-benzo-
xazole, N-benzothiazole, N-pyridine and N-pyrimidine deriva-
tives 2a–c, 3a–c, 4b,c and 7b,c (Scheme 4). The base-catalyzed
rearrangements of N-substituted derivatives of 3-arylamino-
isoxazol-5(2H)-ones 1 appears to be generally applicable to the
synthesis of new planar polycyclic heterocycles.
Experimental
General
Freshly distilled solvents were used and anhydrous solvents
were dried according to Perrin and Armarego.12 Melting points
were determined on a Philip Harris C4954718 apparatus and are
uncorrected. Infrared spectra were recorded on a Thermonicolet
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(Nexus 670) FT-infrared spectrometer, using sodium chloride
cells and measured as Nujol mulls or KBr. 1H (300 MHz) and
13C (75.5 MHz) NMR measurements were recorded on a
Bruker 300 spectrometer in DMSO-d6 or CDCl3 using TMS as the
internal reference. High-resolution mass spectra were recorded
on a Varian Matt 311 spectrometer. Mass spectra were recorded
on a HP 5973 MSD instrument connected to a HP 6890 GC. Rela-
tive abundances of fragments are quoted in brackets after the
m/z values. The reactions were performed in a microwave oven
(DeLonghi, model number CE290DN).
Typical Procedure
A mixture of isoxazolone 1 (2 mmol) and chloroheterocycle
(2 mmol) was mixed and ground in a mortar and pestle until a
fine homogeneous powder was obtained (5 min). The mixture
was then irradiated under microwave irradiation for 5 min at
130 °C. The resulting product was recrystalized from ethanol to
give the corresponding N-aryl isoxazolone.
Ethyl 2-(benzoxazol-2-yl)-3-phenylamino-5-oxo-2, 5-dihydro-
isoxazole-4-carboxylate (2a)
As white needles (66 mg, 90 %), mp 113–114 °C (lit.6 114–116 °C)
1H NMR (CDCl3) Ç 1.40 (t, J = 7.0 Hz, 3H), 4.41 (q, J = 7.0 Hz, 2H),
6.94 (t, J = 7.1 Hz, 1H, Ar), 7.11 (t, J = 7.4 Hz, 2H, Ar), 7.17 (d, J =
7.5 Hz, 2H, Ar), 7.27 (t, J = 7.6 Hz, 1H, Ar), 7.34 (t, J = 7.1 Hz, 1H,
Ar), 7.42 (d, J = 8.0 Hz, 1H, Ar), 7.46 (d, J = 7.7 Hz, 1H, Ar), 9.96 (s,
exchanged by D2O addition, 1H, NH).
13CNMR (CDCl3) Ç 14.78,
61.54, 79.11, 111.26, 120.98, 122.85, 125.83, 127.26, 129.76, 135.63,
139.71, 150.04, 151.58, 164.55, 165.21. FT-IR (KBr) åmax cm
–1: 3270,
2990, 1784, 1668, 1628, 1489, 1201, 1030, 761, 704. GC-MS (EI,
70ev): m/z (%) 365 (M+, 13), 321 [(M-CO2), 14], 276 (32), 275(100),
236 (32), 217 (11), 216 (62), 145 (23), 144 (82), 78(17), 77 (76), 44 (42),
29 (58).
Ethyl 2-(benzoxazol-2-yl)-3-(4-bromophenylamino)-5-oxo-2,
5-dihydroisoxazole-4-carboxylate (2b)
As white needles (0.82g, 92 %), mp 151–152 °C (lit.6 151–153 °C).
1H NMR(CDCl3) Ç 1.45 (t, J = 7.1 Hz, 3H), 4.44 (q, J = 7.1 Hz, 2H),
7.11 (d, J = 8.7 Hz, 2H, Ar), 7.30 (d, J = 8.7 Hz, 2H, Ar), 7.36 (t,
J = 7.7 Hz, 1H, Ar), 7.42 (t, J = 7.4 Hz, 1H, Ar), 7.51 (d, J = 8.2 Hz,
1H, Ar), 7.54 (d, J = 8.0 Hz, 1H, Ar), 9.99 (s, exchanged by D2O
addition, 1H, NH). 13C NMR (CDCl3) Ç 14.76, 61.70, 79.68, 111.35,
120.60, 121.06, 124.30, 126.02, 127.35, 132.92, 134.97, 139.72,
150.12, 151.60, 163.61, 164.38, 165.24. FT-IR (KBr) åmax cm
–1: 3238,
2978, 1786, 1672, 1627, 1204, 786, 746. GC-MS (EI,70ev): m/z (%)
443 [(M+ + 2), 3], 441 (M+, 3), 399 [(M-CO2), 26], 397 [(M-CO2), 26],
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355 (21), 353 (21), 275 (28), 274 (95), 246 (21), 216 (36), 173 (24), 145
(33), 117(40), 102 (30), 90 (41), 77 (37), 44 (30), 43 (68), 29 (100).
Ethyl 2-(benzoxazol-2-yl)-3-(4-methylphenylamino)-5-oxo-2,
5-dihydroisoxazole-4-carboxylate (2c)
As white needles (0.68 g, 90 %), mp 130–132 °C (lit.6 129–131
°C). 1H NMR (CDCl3) Ç 1.45 (t, J = 7.1 Hz, 3H), 2.12 (s, 3H), 4.45 (q,
J = 7.1 Hz, 2H), 6.92 (d, J = 7.9 Hz, 2H, Ar), 7.08 (d, J = 7.9 Hz, 2H,
Ar), 7.33 (t, J = 7.7 Hz, 1H, Ar), 7.40 (t, J = 8.2 Hz, 1H, Ar), 7.47 (d,
J = 8.2 Hz, 1H, Ar), 7.53 (d, J = 7.9 Hz, 1H, Ar), 9.90 (s, exchanged
by D2O addition, 1H, NH).
13C NMR (CDCl3) Ç 14.81, 21.11, 61.50,
78.91, 111.27, 121.08, 122.94, 125.74, 127.13, 130.29, 132.99, 137.44,
139.91,150.15, 151.76, 164.01, 164.85, 165.38. FT-IR (KBr) åmax cm
–1:
3267, 1790, 1683, 1667, 1632, 1561, 1514, 1356, 1293, 1201, 1030,
985, 791. GC-MS (EI, 70 ev): m/z (%) 379 (M+, 7), 335 [(M-CO2),
34], 290 (23), 289 (100), 251(11), 250 (46), 230 (57), 158 (60), 117 (55),
91 (100), 77(44), 65 (50), 44 (9), 29 (66).
Ethyl 2-(benzothiazol-2-yl)-3-phenylamino-5-oxo-2,
5-dihydroisoxazole-4-carboxylate (3a)
As white prisms (0.7 g, 92 %), mp 140–143 °C (lit.5 141–142 °C).
1H NMR (CDCl3) Ç 1.29 (t, J = 7.1Hz, 3H), 4.27 (q, J = 7.1Hz, 2H),
7.04–7.08 (m, 1H), 7.18–7.23 (m, 4H), 7.35 (td, J1 = 7.6 Hz, J2=
1.3 Hz, 1H), 7.40 (td, J1 = 7.6 Hz, J2 = 1.3 Hz, 1H), 7.65 (dd, J1 = 7.9
Hz, J2 = 0.88 Hz, 1H), 7.76 (dd, J1 = 7.75 Hz, J2 = 1 Hz, 1H), 10.15
(s, 1H, exchanged by D2O addition, NH).
13C NMR (CDCl3)
Ç 14.30, 60.97, 78.72, 121.56, 122.48, 123.01, 125.92, 126.54, 126.93,
129.20, 133.47, 136.72, 149.12, 157.23, 161.68, 163.35, 163.99. FT-IR
(KBr) åmax/cm
–1: 3190, 1782, 1686, 1569, 1497, 1456, 1442, 1378, 1282,
1224, 1177, 950, 765.
Ethyl 2-(benzothiazol-2-yl)-3-(4-bromophenyl) amino-5-oxo-2,
5-dihydro-4-carboxylate (3b)
As white needles (0.85 g, 92 %), mp 172–173 °C (lit.6 172–174 °C).
1H NMR (CDCl3) Ç 1.34 (t, J = 6.9 Hz, 3H), 4.33 (q, J = 6.9 Hz, 2H),
7.1 (d, J = 8.7 Hz, 2H, Ar), 7.36 (d, J = 8.7 Hz, 2H, Ar), 7.40 (td,
J = 7.5 Hz, J = 1.5 Hz, 1H, Ar), 7.46 (td, J = 7.2 Hz, J = 1.5 Hz, 1H,
Ar), 7.67 (d, J = 7.5 Hz, 1H, Ar), 7.81 (d, J = 7.5 Hz, 1H, Ar), 10.16 (s,
exchanged by D2O addition, 1H, NH).
13C NMR(CDCl3) Ç 14.31,
61.14, 79.10, 119.70, 121.62, 122.98, 123.93, 126.03, 127.10, 132.27,
136.00, 149.08, 157.19, 161.43, 163.02, 163.94. FT-IR (KBr) åmax cm
–1:
3188, 2971, 1783, 1696, 1602, 1556, 1515, 1371, 1204, 764. GC-MS
(EI, 70ev):m/z (%) 461 [(M+ + 2), 4], 459 (M+, 4), 417 [(M-CO2), 31],
415 [(M-CO2), 30], 371 (25), 369 (23), 291 (23), 290 (100), 263 (12),
262 (26), 224 (11), 177 (14), 161 (16), 135 (11), 134(15), 108 (10), 29
(13).
Ethyl 2-(benzothiazol-2-yl)-3-(4-methylphenyl)
amino-5-oxo-2, 5-dihydro-4-carboxylate (3c)
As white needles (0.75 g, 95 %), mp 139–141 °C (lit.6 138–140 °C).
1H NMR (CDCl3) Ç 1.35 (t, J = 7.2 Hz, 3H), 2.31 (s, 3H), 4.27(q,
J = 7.2 Hz, 2H), 7.00 (d, J = 8.1 Hz, 1H, Ar), 7.07 (d, J = 7.2Hz, 1H,
Ar), 7.27 (d, J = 6.9 Hz, 1H, Ar), 7.30–7.52 (m, 2H, Ar), 7.69 (d,
J = 8.1 Hz, 1H, Ar), 7.87 (d, J = 7.8 Hz, 1H, Ar),7.93 (d, J = 8.1 Hz,
1H, Ar), 9.21 (s, exchanged by D2O addition, 1H, NH).
13C NMR
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(CDCl3) Ç 14.46, 20.88, 60.47, 75.55, 121.12, 121.76, 122.53, 122.85,
125.81, 126.74, 126.93, 129.74, 130.43, 132.68, 136.45, 164.51,
165.41, 167.25. FT-IR (KBr) åmax cm
–1: 3218, 3075, 1979, 1778, 1708,
1573, 1448, 1390, 1201, 726.
Ethyl 3-(4-bromophenyl) amino-2-(5-nitropyrid-2-yl)-5-oxo-2,
5-dihydroisoxazole-4-carboxylate (4b)
As yellow crystals (0.85 g, 95 %), mp 216–218 °C (lit.7 218 °C).
1HNMR (d6-DMSO+CDCl3): Ç 0.99 (t, J = 7 Hz, 3H), 3.94 (q,
J = 7 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 7.73
(d, J = 9.1 Hz, 1H), 8.40 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H), 8.75
(d, J = 2.3 Hz, 1H), 10.29 (br s, 1H, NH); 13C NMR (d6-DMSO+
CDCl3): Ç 14.41, 60.99, 79.05, 114.63, 119.46, 124.11, 132.46, 135.08,
137.21, 141.66, 143.79, 153.92, 158.31, 161.38, 165.88; FT-IR (KBr)
åmax cm
–1: 3140, 2965, 1773, 1683, 1591, 1531, 1324, 1188, 1114, 1010,
961, 832; MS m/z: 450 (M++2, 27 %), 448(M+, 30 %), 406(74),
404(77), 279(100), 251(20), 184(35), 182(36), 157(29), 155(29),
102(22), 72(23), 44(59).
Ethyl 3-(4-methylphenyl) amino-2-(5-nitropyrid-2-yl)-5-oxo-2,
5-dihydroisoxazole-4-carboxylate (4c)
As orange needles (0.7 g, 92 %) mp 62–64 °C (lit.9 59–61 °C).
1H NMR (CDCl3): Ç 10.31 (br s, 1H), 8.89 (d, 1H, J = 2.7 Hz), 8.53
(dd, 1H, J1 = 9.1, J2 = 2.7 Hz), 7.52 (d, 1H, J = 9.1 Hz), 7.03 (br s,
4H), 4.23 (q, 2H, J = 7.1 Hz), 2.27 (s, 3H), 1.26 (t, 3H, J = 7.1 Hz);
13C NMR Ç 163.8, 163.1, 160.6, 153.9, 143.5, 141.5, 136.4, 135.0,
134.2, 129.9, 122.0, 115.0, 78.7, 60.9, 20.9, 14.2. FT-IR (KBr) åmax
cm–1: 3389, 1780, 1669, 1602, 1525, 1456, 1419, 1337.
Ethyl 5-oxo-3-(4-bromophenylamino)-2-(pyrimidin-2-yl)-2,
5-dihydroisoxazole-4-carboxylate (7b)
As white prisms (0.64 g, 95 %), mp 202–204 °C (lit.13 202–204 °C).
1H NMR (CDCl3): 1.36 (t, J = 7.2 Hz, 3H), 4.33(q, J = 7.2 Hz, 2H),
7.05 (d, J = 8.7 Hz, 2H, Ar), 7.14 (t, J = 4.8 Hz, 1H, Ar), 7.32 (d,
J = 8.7 Hz, 2H, Ar), 8.57 (d, J = 4.8 Hz, 2H, Ar), 10.19 (s, 1H, NH,
removed by D2O addition);
13C NMR (CDCl3): 14.33, 60.96,
79.27, 118.96, 119.37, 123.24, 132.29, 136.56, 156.16, 158.59, 161.13,
163.44, 164.58 ppm; FT-IR (KBr) åmax cm
–1: 3310, 3208, 3083, 1759,
1698, 1601, 1578, 1556, 1392, 1069, 835, 781.
Ethyl 5-oxo-2-(pyrimidin-2-yl)-3-(p-tolylamino)-2, 5-dihydro-
isoxazole-4-carboxylate (7c)
As pale yellow prisms (0.77 g, 95 %), mp 187–189 °C (lit.13
187–189 °C). 1H NMR (CDCl3): 1.35 (t, J = 7.2 Hz, 3H), 2.23 (s,
3H), 4.32 (q, J = 7.1 Hz, 2H), 6.98 (d, J = 8.7 Hz, 2H, Ar), 7.03 (d,
J = 8.7 Hz, 2H, Ar), 7.09 (t, J = 4.8 Hz, 1H, Ar), 8.53 (d, J = 4.8 Hz,
2H, Ar), 10.10 (s, 1H, NH, removed by D2O addition);
13C NMR
(CDCl3): 14.36, 20.85, 60.78, 78.62, 119.24, 121.71, 129.73, 134.64,
135.83, 156.35, 158.48, 161.61, 163.87, 164.74; FT-IR (KBr) åmax/cm
–1:
3207, 3083, 2985, 1761, 1699, 1579, 1558, 1393, 1371, 1069, 781.
4. Conclusion
In conclusion, we have developed a rapid, convenient and
efficient method for synthesis of N-aryl isoxazolones under
solvent-free conditions. The main advantages of this method
are: (i) elimination of the nitrogen gas (N2), (ii) solvent-free
conditions, (iii) microwave irradiation, (iv) avoiding the use of
silica gel for purification of the products, and (v) higher and
shorter reaction times. The synthesis of N-aryl isoxazolones
appear to be generally applicable to the synthesis of hetero-
cycles, which are suitable synthetic intermediates for a series of
new polycyclic heterocycles with possible pharmaceutical appli-
cations and they are expected to intercalate with DNA.14–16
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